论文部分内容阅读
目的:研究卡维地洛对慢性心力衰竭患者血清Th7细胞功能的影响。方法:48例慢性心力衰竭患者随机分为常规治疗组(23例)和卡维地洛组(25例),另选取20例健康体检者为健康对照组。于治疗前和治疗6个月时检测血清中Th17型细胞因子白介素-17(IL-17)及其相关因子IL-6、IL-23的水平。结果:慢性心力衰竭患者血清中IL-17及IL-6、IL-23水平明显高于健康对照组(P<0.01)。与治疗前相比,治疗6个月后卡维地洛组和常规治疗组患者IL-17及IL-6,IL-23水平均有明显下降(P<0.01),且卡维地洛组上述指标均显著低于常规治疗组(P<0.05)。结论:慢性心力衰竭患者存在Th17细胞功能亢进,卡维地洛可以明显下调Th17细胞功能,该效应可能是卡维地洛改善慢性心力衰竭患者心功能的作用机制之一。
Objective: To study the effect of carvedilol on serum Th7 cell function in patients with chronic heart failure. Methods: Forty-eight patients with chronic heart failure were randomly divided into conventional treatment group (23 cases) and carvedilol group (25 cases). Another 20 healthy subjects were selected as healthy control group. Serum levels of Th17 cytokine interleukin-17 (IL-17) and its related factors IL-6 and IL-23 were measured before treatment and at 6 months of treatment. Results: Serum levels of IL-17, IL-6 and IL-23 in patients with chronic heart failure were significantly higher than those in healthy controls (P <0.01). Compared with those before treatment, the levels of IL-17, IL-6 and IL-23 in the carvedilol group and the routine treatment group were significantly decreased after 6 months of treatment (P <0.01), and the carvedilol group Indicators were significantly lower than the conventional treatment group (P <0.05). CONCLUSION: Th17 cell hyperfunction exists in patients with chronic heart failure. Carvedilol can down-regulate the function of Th17 cells. This effect may be one of the mechanisms of carvedilol improving cardiac function in patients with chronic heart failure.